These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26883295)

  • 21. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
    Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
    J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.
    Talavera A; Friemann R; Gómez-Puerta S; Martinez-Fleites C; Garrido G; Rabasa A; López-Requena A; Pupo A; Johansen RF; Sánchez O; Krengel U; Moreno E
    Cancer Res; 2009 Jul; 69(14):5851-9. PubMed ID: 19584289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody.
    Pacchiana G; Chiriaco C; Stella MC; Petronzelli F; De Santis R; Galluzzo M; Carminati P; Comoglio PM; Michieli P; Vigna E
    J Biol Chem; 2010 Nov; 285(46):36149-57. PubMed ID: 20833723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imaging Potential Evaluation of Fab Derived from the Anti-EGFRvIII Monoclonal Antibody 4G1.
    Jing S; He Y; He Y; Wang L; Jia J; Shan X; Liu S; Tang M; Peng Z; Liu X
    Radiat Res; 2018 Aug; 190(2):194-203. PubMed ID: 29848174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
    Dong X; Jin K; Hu X; Du F; Lan H; Han N; Ma Z; Xie B; Cui B; Teng L; Cao F
    Int J Mol Med; 2012 Jul; 30(1):126-32. PubMed ID: 22505231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and Evaluation of a Cetuximab-based Humanized Single Chain Antibody Against EGFR-overexpressing Tumors.
    Veisi K; Farajnia S; Zarghami N; Khorshid HR; Samadi N; Safdari Y; Ahmadzadeh V
    Drug Res (Stuttg); 2015 Dec; 65(12):624-8. PubMed ID: 25333654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
    Schmiedel J; Blaukat A; Li S; Knöchel T; Ferguson KM
    Cancer Cell; 2008 Apr; 13(4):365-73. PubMed ID: 18394559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
    Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
    J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effective therapeutic approach for head and neck cancer by an engineered minibody targeting the EGFR receptor.
    Kim YP; Park D; Kim JJ; Chi WJ; Lee SH; Lee SY; Kim S; Chung JM; Jeon J; Lee BD; Shin JH; Lee YI; Cho H; Lee JM; Kang HC
    PLoS One; 2014; 9(12):e113442. PubMed ID: 25438047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation.
    Wang H; Shi B; Zhang Q; Jiang H; Hu S; Kong J; Yao M; Yang S; Li Z
    FASEB J; 2012 Jan; 26(1):73-80. PubMed ID: 21917986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding of EGF peptide and EGF receptor antibodies and its fragments in different tumor models.
    Senekowitsch-Schmidtke R
    Hybridoma; 1999 Feb; 18(1):29-35. PubMed ID: 10211785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.
    Overdijk MB; Verploegen S; van den Brakel JH; Lammerts van Bueren JJ; Vink T; van de Winkel JG; Parren PW; Bleeker WK
    J Immunol; 2011 Sep; 187(6):3383-90. PubMed ID: 21832160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
    Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
    Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conjugation effects on antibody-drug conjugates: evaluation of interaction kinetics in real time on living cells.
    Bondza S; Stenberg J; Nestor M; Andersson K; Björkelund H
    Mol Pharm; 2014 Nov; 11(11):4154-63. PubMed ID: 25252166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single domain antibodies: a new concept for epidermal growth factor receptor and EGFRvIII targeting.
    Omidfar K; Shirvani Z
    DNA Cell Biol; 2012 Jun; 31(6):1015-26. PubMed ID: 22277093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody.
    Watanabe Y; Asano R; Arai K; Shimomura I; Ogata H; Kawaguchi H; Hayashi H; Ohtsuka H; Yoshida H; Katayose Y; Egawa S; Nakanishi T; Umetsu M; Yasui H; Ishida T; Imai K; Kudo T; Unno M; Kumagai I
    Oncol Rep; 2011 Oct; 26(4):949-55. PubMed ID: 21743971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade.
    Kasper S; Breitenbuecher F; Reis H; Brandau S; Worm K; Köhler J; Paul A; Trarbach T; Schmid KW; Schuler M
    Oncogene; 2013 Jun; 32(23):2873-81. PubMed ID: 22797062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 99mTc-Hydrazinonicotinamide epidermal growth factor-polyethylene glycol-quantum dot imaging allows quantification of breast cancer epidermal growth factor receptor expression and monitors receptor downregulation in response to cetuximab therapy.
    Jung KH; Choe YS; Paik JY; Lee KH
    J Nucl Med; 2011 Sep; 52(9):1457-64. PubMed ID: 21849406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.